Embla Medical hf Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Embla Medical hf ha aumentado sus beneficios a una tasa media anual de 6%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 1.9% anual. Los ingresos han ido creciendo a una tasa media de 4.9% al año. La rentabilidad financiera de Embla Medical hf es de 8.8%, y sus márgenes netos son de 8.2%.

Información clave

6.0%

Tasa de crecimiento de los beneficios

5.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	-9.5%
Tasa de crecimiento de los ingresos	4.9%
Rentabilidad financiera	8.8%
Margen neto	8.2%
Próxima actualización de resultados	05 Feb 2025

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Embla Medical hf. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

LSE:0FIW Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 24	840	69	375	40
30 Jun 24	820	61	371	39
31 Mar 24	804	57	368	38
31 Dec 23	786	58	360	38
30 Sep 23	766	52	353	37
30 Jun 23	750	45	354	36
31 Mar 23	730	43	345	34
31 Dec 22	719	43	339	34
30 Sep 22	715	47	339	34
30 Jun 22	719	57	331	33
31 Mar 22	728	62	331	34
31 Dec 21	719	64	328	32
30 Sep 21	701	50	323	32
30 Jun 21	692	48	318	31
31 Mar 21	637	11	308	31
31 Dec 20	630	6	307	31
30 Sep 20	639	20	303	30
30 Jun 20	635	19	308	30
31 Mar 20	680	59	311	31
31 Dec 19	686	66	308	31
30 Sep 19	675	83	296	31
30 Jun 19	652	85	284	31
31 Mar 19	631	83	274	31
31 Dec 18	613	80	265	31
30 Sep 18	599	69	259	31
30 Jun 18	593	64	254	31
31 Mar 18	579	58	252	30
31 Dec 17	569	58	245	29
30 Sep 17	553	49	246	29
30 Jun 17	543	51	239	27
31 Mar 17	538	52	240	25
31 Dec 16	521	51	233	23
30 Sep 16	507	49	227	21
30 Jun 16	495	50	219	20
31 Mar 16	483	51	209	19
31 Dec 15	483	51	208	18
30 Sep 15	488	54	209	18
30 Jun 15	497	55	213	18
31 Mar 15	502	57	214	19
31 Dec 14	509	59	218	19
30 Sep 14	509	58	217	20
30 Jun 14	487	55	207	20
31 Mar 14	460	46	199	21
31 Dec 13	436	40	189	22

Ingresos de calidad: 0FIW tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (8.2%) de 0FIW son superiores a los del año pasado (6.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de 0FIW han crecido un 6% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de 0FIW en el último año (32.1%) supera su media de 5 años (6% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de 0FIW en el último año (32.1%) no superó al de la industria Medical Equipment 39.9%.

Embla Medical hf Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.10 in FY 2022)

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Full year 2022 earnings released

Recent updates

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Less than half of directors are independent

Less than half of directors are independent

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Less than half of directors are independent

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

Less than half of directors are independent

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Less than half of directors are independent

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.10 in FY 2022)

Össur hf. Provides Earnings Guidance for the Year 2024

Less than half of directors are independent

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Less than half of directors are independent

Össur hf. Reaffirms Financial Guidance for the Year 2023

Less than half of directors are independent

Össur hf. Announces Executive Changes

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Less than half of directors are independent

Less than half of directors are independent

Össur hf. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Less than half of directors are independent

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Less than half of directors are independent

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Less than half of directors are independent

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Less than half of directors are independent

Össur Launches New POWER KNEE

Össur hf. Announces Sales Guidance for the Full Year 2022

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Össur Hf. Announces Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$0.027 (vs US$0.017 in 1Q 2020)

Össur Hf. Provides Financial Guidance for the Full Year 2021

Vice Chairman Kristján Ragnarsson has left the company

Full year 2020 earnings released: EPS US$0.015 (vs US$0.16 in FY 2019)

Revenue misses expectations

Össur hf., Annual General Meeting, Mar 08, 2022

Laboratoires Innothera S.A.S completed the acquisition of Gibaud SAS from Össur hf. (CPSE:OSSR).

Össur Hf. Withdraw Its Financial Guidance for 2020

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado